Derma Sciences (Derma Sciences) Payments on Behalf of Employees

Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. In addition, the Company owns or licenses over 50 U.S. patents, corresponding foreign patents and patent applications. The patents relating to the DSC127, MEDIHONEY, BIOGUARD, AMNIOEXCEL and AMNIOMATRIX technologies are held under license agreements of indefinite duration. It is subject to the regulation regarding occupational safety, laboratory practices, environmental protection and hazardous substance control and may be subject to other present and future U.S. and foreign regulations.